• originalucifer
    link
    fedilink
    15 months ago

    At a meeting Monday, the Peripheral and Central Nervous System Drugs Advisory Committee voted 11-0 that donanemab is effective at slowing down Alzheimer’s in the disease’s early stages

    this is how efficacy is determined? by committees voting?? seems weird

    • @[email protected]
      link
      fedilink
      English
      65 months ago

      Presumably the committee members would be experts in their field that would weigh the evidence accordingly and come to a decision. They would vote because it’s a better failsafe than having one guy just sign off on the whole thing.

      No idea of that’s how it works in practice, but it does make sense imo.